HIV, Hetero and Gilead Sciences
Hetero enters into agreement with Gilead to manufacture and distribute multi drug-resistant HIV
Lenacapavir was approved for use in HIV-positive adults with multi-drug resistance by the European Union in August 2022 and received U.S. FDA approval in December 2022.
Hetero Inks Voluntary Licensing Pact with Gilead for HIV Drug Lenacapavir
Hetero has partnered with Gilead Sciences to manufacture and distribute the HIV drug lenacapavir in 120 low- and middle-income countries, aiming to improve access to treatment and prevention. Lenacapavir,
Dr Reddy's, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir
Dr Reddy's Laboratories and Hetero, along with other generic drug makers, enter into voluntary licensing agreements with Gilead Sciences to produce and distribute HIV drug Lenacapavir in India and 120 LMICs.
Dr. Reddy’s and Hetero join hands with Gilead to broaden access to HIV drug Lenacapavir in low-income countries
Dr. Reddy’s and Hetero partner with Gilead Sciences to manufacture and distribute Lenacapavir for HIV treatment in LMICs.
Hetero-Gilead Partnership to Broaden Access to Innovative HIV Drug
Pharmaceutical firm Hetero has partnered with Gilead Sciences Ireland UC to manufacture and distribute the HIV treatment drug lenacapavir in 120 primarily low- and lower-middle-income countries. The collaboration aims to broaden access,
Dr Reddy’s, Hetero ink royalty-free pact with Gilead
Dr Reddy's Laboratories and Hetero sign non-exclusive, royalty-free agreements with Gilead Sciences to manufacture Lenacapavir for HIV treatment in India and 120 LMICs, enhancing access for heavily treatment-experienced adults.
Hetero & Gilead Partner for HIV Drug Lenacapavir Access
Hetero and Gilead have partnered to expand access to lenacapavir, a groundbreaking HIV treatment, in 120 low- and middle-income countries. This partnership aims to improve treatment options and expand HIV prevention through PrEP.
Dr Reddy's, Hetero sign voluntary licenses with Gilead for HIV drug
Gilead Sciences first launched lenacapavir under the brand name Sunlenca in the United States and European markets in 2022. It is a first-in-class HIV-1 capsid inhibitor
Gilead Sciences inks pacts with Dr Reddy's Labs, Emcure, Hetero and 3 others for HIV drug Lenacapavir
Gilead Sciences, Inc. has announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell
Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries
Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its HIV prevention medicine in 120 low and lower-middle income countries.
Gilead Licenses HIV-prevention Drug To Generic Drugmakers
US pharmaceutical giant Gilead said Wednesday it had signed licensing deals with six generic drugmakers to produce and sell its HIV prevention medicine in lower-income countries.
Image1d
Hetero-exceptionalism is the new form of blaming women for systemic inequality
The research is in: heteronormative marriage systemically disadvantages women and perpetuates inequality and women’s ...
pv magazine International18h
Perovskite solar module achieves 21.44% efficiency via new passivation tech
Researchers have developed a novel passivation process for formamidinium lead iodide perovskite films, which reportedly ...